Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

The Human Vaccines Project: Towards a comprehensive understanding of the human immune response to immunization.

Wooden SL, Koff WC.

Hum Vaccin Immunother. 2018;14(9):2214-2216. doi: 10.1080/21645515.2018.1476813. Epub 2018 Jun 28. Review.

2.

A bioinformatics roadmap for the human vaccines project.

Scheuermann RH, Sinkovits RS, Schenkelberg T, Koff WC.

Expert Rev Vaccines. 2017 Jun;16(6):535-544. doi: 10.1080/14760584.2017.1322752. Epub 2017 May 9. Review.

PMID:
28434256
4.

Novel approaches in preclinical HIV vaccine research.

Safrit JT, Koff WC.

Curr Opin HIV AIDS. 2016 Nov;11(6):601-606. Review.

PMID:
27636502
5.

Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies.

Deshpande S, Patil S, Kumar R, Shrivastava T, Srikrishnan AK, Murugavel KG, Koff WC, Chakrabarti BK, Bhattacharya J.

Retrovirology. 2016 Jun 15;13(1):41. doi: 10.1186/s12977-016-0273-x.

6.

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.

Kong R, Xu K, Zhou T, Acharya P, Lemmin T, Liu K, Ozorowski G, Soto C, Taft JD, Bailer RT, Cale EM, Chen L, Choi CW, Chuang GY, Doria-Rose NA, Druz A, Georgiev IS, Gorman J, Huang J, Joyce MG, Louder MK, Ma X, McKee K, O'Dell S, Pancera M, Yang Y, Blanchard SC, Mothes W, Burton DR, Koff WC, Connors M, Ward AB, Kwong PD, Mascola JR.

Science. 2016 May 13;352(6287):828-33. doi: 10.1126/science.aae0474.

7.

A shot at AIDS.

Koff WC.

Curr Opin Biotechnol. 2016 Dec;42:147-151. doi: 10.1016/j.copbio.2016.03.007. Epub 2016 May 3. Review.

PMID:
27153215
8.

Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G.

Stewart-Jones GB, Soto C, Lemmin T, Chuang GY, Druz A, Kong R, Thomas PV, Wagh K, Zhou T, Behrens AJ, Bylund T, Choi CW, Davison JR, Georgiev IS, Joyce MG, Kwon YD, Pancera M, Taft J, Yang Y, Zhang B, Shivatare SS, Shivatare VS, Lee CC, Wu CY, Bewley CA, Burton DR, Koff WC, Connors M, Crispin M, Baxa U, Korber BT, Wong CH, Mascola JR, Kwong PD.

Cell. 2016 May 5;165(4):813-26. doi: 10.1016/j.cell.2016.04.010. Epub 2016 Apr 21.

9.

Decoding the human immune system to transform the future of global disease prevention and control.

Koff WC, Schenkelberg T.

Expert Rev Vaccines. 2016 Oct;15(10):1235-6. doi: 10.1586/14760584.2016.1170600. Epub 2016 May 25. No abstract available.

PMID:
27010379
10.

Status of vaccine research and development of vaccines for HIV-1.

Safrit JT, Fast PE, Gieber L, Kuipers H, Dean HJ, Koff WC.

Vaccine. 2016 Jun 3;34(26):2921-2925. doi: 10.1016/j.vaccine.2016.02.074. Epub 2016 Mar 15.

11.

Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.

Patil S, Kumar R, Deshpande S, Samal S, Shrivastava T, Boliar S, Bansal M, Chaudhary NK, Srikrishnan AK, Murugavel KG, Solomon S, Simek M, Koff WC, Goyal R, Chakrabarti BK, Bhattacharya J.

J Virol. 2016 Jan 13;90(7):3446-57. doi: 10.1128/JVI.03090-15.

12.

Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes.

de Taeye SW, Ozorowski G, Torrents de la Peña A, Guttman M, Julien JP, van den Kerkhof TL, Burger JA, Pritchard LK, Pugach P, Yasmeen A, Crampton J, Hu J, Bontjer I, Torres JL, Arendt H, DeStefano J, Koff WC, Schuitemaker H, Eggink D, Berkhout B, Dean H, LaBranche C, Crotty S, Crispin M, Montefiori DC, Klasse PJ, Lee KK, Moore JP, Wilson IA, Ward AB, Sanders RW.

Cell. 2015 Dec 17;163(7):1702-15. doi: 10.1016/j.cell.2015.11.056.

13.

Deciphering the human antigenome.

Sette A, Schenkelberg TR, Koff WC.

Expert Rev Vaccines. 2016;15(2):167-71. doi: 10.1586/14760584.2016.1112743. Epub 2015 Dec 2.

PMID:
26629807
14.

Deciphering the human immunome.

Crowe JE Jr, Koff WC.

Expert Rev Vaccines. 2015;14(11):1421-5. doi: 10.1586/14760584.2015.1082427. Epub 2015 Aug 24.

PMID:
26485213
15.

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.

Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, Arendt H, Kim HJ, Lee JH, Pugach P, Williams M, Debnath G, Moldt B, van Breemen MJ, Isik G, Medina-Ramírez M, Back JW, Koff WC, Julien JP, Rakasz EG, Seaman MS, Guttman M, Lee KK, Klasse PJ, LaBranche C, Schief WR, Wilson IA, Overbaugh J, Burton DR, Ward AB, Montefiori DC, Dean H, Moore JP.

Science. 2015 Jul 10;349(6244):aac4223. doi: 10.1126/science.aac4223. Epub 2015 Jun 18.

16.

Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors.

Zhou T, Lynch RM, Chen L, Acharya P, Wu X, Doria-Rose NA, Joyce MG, Lingwood D, Soto C, Bailer RT, Ernandes MJ, Kong R, Longo NS, Louder MK, McKee K, O'Dell S, Schmidt SD, Tran L, Yang Z, Druz A, Luongo TS, Moquin S, Srivatsan S, Yang Y, Zhang B, Zheng A, Pancera M, Kirys T, Georgiev IS, Gindin T, Peng HP, Yang AS; NISC Comparative Sequencing Program, Mullikin JC, Gray MD, Stamatatos L, Burton DR, Koff WC, Cohen MS, Haynes BF, Casazza JP, Connors M, Corti D, Lanzavecchia A, Sattentau QJ, Weiss RA, West AP Jr, Bjorkman PJ, Scheid JF, Nussenzweig MC, Shapiro L, Mascola JR, Kwong PD.

Cell. 2015 Jun 4;161(6):1280-92. doi: 10.1016/j.cell.2015.05.007. Epub 2015 May 21.

17.

Building the Human Vaccines Project: strategic management recommendations and summary report of the 15-16 July 2014 business workshop.

Schenkelberg T, Kieny MP, Bianco AE, Koff WC.

Expert Rev Vaccines. 2015 May;14(5):629-36. doi: 10.1586/14760584.2015.1013466. Epub 2015 Feb 11. Review.

PMID:
25673514
18.

Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcoding.

He L, Sok D, Azadnia P, Hsueh J, Landais E, Simek M, Koff WC, Poignard P, Burton DR, Zhu J.

Sci Rep. 2014 Oct 27;4:6778. doi: 10.1038/srep06778.

19.

Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions.

Munro JB, Gorman J, Ma X, Zhou Z, Arthos J, Burton DR, Koff WC, Courter JR, Smith AB 3rd, Kwong PD, Blanchard SC, Mothes W.

Science. 2014 Nov 7;346(6210):759-63. doi: 10.1126/science.1254426. Epub 2014 Oct 8.

20.

Transplanting supersites of HIV-1 vulnerability.

Zhou T, Zhu J, Yang Y, Gorman J, Ofek G, Srivatsan S, Druz A, Lees CR, Lu G, Soto C, Stuckey J, Burton DR, Koff WC, Connors M, Kwong PD.

PLoS One. 2014 Jul 3;9(7):e99881. doi: 10.1371/journal.pone.0099881. eCollection 2014. Erratum in: PLoS One. 2014;9(8); e105659. doi: 10.1371/journal.pone.0105659. Kwon, Peter D [corrected to Kwong, Peter D].

21.

Toward a human vaccines project.

Koff WC, Gust ID, Plotkin SA.

Nat Immunol. 2014 Jul;15(7):589-92. doi: 10.1038/ni.2871. No abstract available.

PMID:
24940943
22.

Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.

Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, Ramirez A, Derking R, van Gils MJ, Liang CH, Mcbride R, von Bredow B, Shivatare SS, Wu CY, Chan-Hui PY, Liu Y, Feizi T, Zwick MB, Koff WC, Seaman MS, Swiderek K, Moore JP, Evans D, Paulson JC, Wong CH, Ward AB, Wilson IA, Sanders RW, Poignard P, Burton DR.

Immunity. 2014 May 15;40(5):657-68. doi: 10.1016/j.immuni.2014.04.009. Epub 2014 Apr 24.

23.

Vaccines that stimulate T cell immunity to HIV-1: the next step.

McMichael AJ, Koff WC.

Nat Immunol. 2014 Apr;15(4):319-22. doi: 10.1038/ni.2844.

24.

Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies.

Zhou T, Zhu J, Wu X, Moquin S, Zhang B, Acharya P, Georgiev IS, Altae-Tran HR, Chuang GY, Joyce MG, Kwon YD, Longo NS, Louder MK, Luongo T, McKee K, Schramm CA, Skinner J, Yang Y, Yang Z, Zhang Z, Zheng A, Bonsignori M, Haynes BF, Scheid JF, Nussenzweig MC, Simek M, Burton DR, Koff WC; NISC Comparative Sequencing Program, Mullikin JC, Connors M, Shapiro L, Nabel GJ, Mascola JR, Kwong PD.

Immunity. 2013 Aug 22;39(2):245-58. doi: 10.1016/j.immuni.2013.04.012. Epub 2013 Aug 1.

25.

Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies.

Amin MN, McLellan JS, Huang W, Orwenyo J, Burton DR, Koff WC, Kwong PD, Wang LX.

Nat Chem Biol. 2013 Aug;9(8):521-6. doi: 10.1038/nchembio.1288. Epub 2013 Jun 30.

26.

Accelerating next-generation vaccine development for global disease prevention.

Koff WC, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ, Ahmed R, Bhan MK, Plotkin SA.

Science. 2013 May 31;340(6136):1232910. doi: 10.1126/science.1232910. Review.

27.

Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.

Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, Dai K, Loesgen S, Louder MK, Staupe RP, Yang Y, Zhang B, Parks R, Eudailey J, Lloyd KE, Blinn J, Alam SM, Haynes BF, Amin MN, Wang LX, Burton DR, Koff WC, Nabel GJ, Mascola JR, Bewley CA, Kwong PD.

Nat Struct Mol Biol. 2013 Jul;20(7):804-13. doi: 10.1038/nsmb.2600. Epub 2013 May 26.

28.

Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines.

Koff WC, Russell ND, Walport M, Feinberg MB, Shiver JW, Karim SA, Walker BD, McGlynn MG, Nweneka CV, Nabel GJ.

Vaccine. 2013 Apr 18;31 Suppl 2:B204-8. doi: 10.1016/j.vaccine.2012.10.115. Review.

PMID:
23598483
29.

Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains.

Zhu J, Ofek G, Yang Y, Zhang B, Louder MK, Lu G, McKee K, Pancera M, Skinner J, Zhang Z, Parks R, Eudailey J, Lloyd KE, Blinn J, Alam SM, Haynes BF, Simek M, Burton DR, Koff WC; NISC Comparative Sequencing Program, Mullikin JC, Mascola JR, Shapiro L, Kwong PD.

Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6470-5. doi: 10.1073/pnas.1219320110. Epub 2013 Mar 27.

30.

N332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function.

Pancera M, Yang Y, Louder MK, Gorman J, Lu G, McLellan JS, Stuckey J, Zhu J, Burton DR, Koff WC, Mascola JR, Kwong PD.

PLoS One. 2013;8(2):e55701. doi: 10.1371/journal.pone.0055701. Epub 2013 Feb 19.

31.

Somatic Populations of PGT135-137 HIV-1-Neutralizing Antibodies Identified by 454 Pyrosequencing and Bioinformatics.

Zhu J, O'Dell S, Ofek G, Pancera M, Wu X, Zhang B, Zhang Z; NISC Comparative Sequencing Program, Mullikin JC, Simek M, Burton DR, Koff WC, Shapiro L, Mascola JR, Kwong PD.

Front Microbiol. 2012 Sep 11;3:315. eCollection 2012.

32.

Influence of HAART on alternative reading frame immune responses over the course of HIV-1 infection.

Champiat S, Raposo RA, Maness NJ, Lehman JL, Purtell SE, Hasenkrug AM, Miller JC, Dean H, Koff WC, Hong MA, Martin JN, Deeks SG, Spotts GE, Pilcher CD, Hecht FM, Kallas EG, Garrison KE, Nixon DF.

PLoS One. 2012;7(6):e39311. doi: 10.1371/journal.pone.0039311. Epub 2012 Jun 29.

33.

A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies.

Doria-Rose NA, Georgiev I, O'Dell S, Chuang GY, Staupe RP, McLellan JS, Gorman J, Pancera M, Bonsignori M, Haynes BF, Burton DR, Koff WC, Kwong PD, Mascola JR.

J Virol. 2012 Aug;86(15):8319-23. doi: 10.1128/JVI.00696-12. Epub 2012 May 23.

34.

A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge.

Reynolds MR, Weiler AM, Piaskowski SM, Piatak M Jr, Robertson HT, Allison DB, Bett AJ, Casimiro DR, Shiver JW, Wilson NA, Lifson JD, Koff WC, Watkins DI.

Vaccine. 2012 Jun 22;30(30):4465-75. doi: 10.1016/j.vaccine.2012.04.082. Epub 2012 May 6.

35.

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.

McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul-Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang LX, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD.

Nature. 2011 Nov 23;480(7377):336-43. doi: 10.1038/nature10696.

36.

HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.

Koff WC.

Vaccine. 2012 Jun 19;30(29):4310-5. doi: 10.1016/j.vaccine.2011.11.014. Epub 2011 Nov 17. Review.

PMID:
22100891
37.

Broad neutralization coverage of HIV by multiple highly potent antibodies.

Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD; Protocol G Principal Investigators, Koff WC, Wilson IA, Burton DR, Poignard P.

Nature. 2011 Sep 22;477(7365):466-70. doi: 10.1038/nature10373.

38.

Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.

Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo NS, Louder M, McKee K, O'Dell S, Perfetto S, Schmidt SD, Shi W, Wu L, Yang Y, Yang ZY, Yang Z, Zhang Z, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Simek M, Burton DR, Koff WC, Doria-Rose NA, Connors M; NISC Comparative Sequencing Program, Mullikin JC, Nabel GJ, Roederer M, Shapiro L, Kwong PD, Mascola JR.

Science. 2011 Sep 16;333(6049):1593-602. doi: 10.1126/science.1207532. Epub 2011 Aug 11.

39.

The TRIM5{alpha} genotype of rhesus macaques affects acquisition of simian immunodeficiency virus SIVsmE660 infection after repeated limiting-dose intrarectal challenge.

Reynolds MR, Sacha JB, Weiler AM, Borchardt GJ, Glidden CE, Sheppard NC, Norante FA, Castrovinci PA, Harris JJ, Robertson HT, Friedrich TC, McDermott AB, Wilson NA, Allison DB, Koff WC, Johnson WE, Watkins DI.

J Virol. 2011 Sep;85(18):9637-40. doi: 10.1128/JVI.05074-11. Epub 2011 Jul 6.

40.

Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge.

Reynolds MR, Weiler AM, Piaskowski SM, Kolar HL, Hessell AJ, Weiker M, Weisgrau KL, León EJ, Rogers WE, Makowsky R, McDermott AB, Boyle R, Wilson NA, Allison DB, Burton DR, Koff WC, Watkins DI.

J Virol. 2010 Sep;84(18):9190-9. doi: 10.1128/JVI.00041-10. Epub 2010 Jun 30.

41.

Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference.

Excler JL, Parks CL, Ackland J, Rees H, Gust ID, Koff WC.

Biologicals. 2010 Jul;38(4):511-21. doi: 10.1016/j.biologicals.2010.03.005.

PMID:
20537552
42.

Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1.

Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, Poignard P, Burton DR, Wilson IA.

Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11483-8. doi: 10.1073/pnas.1004600107. Epub 2010 Jun 2.

43.

Accelerating HIV vaccine development.

Koff WC.

Nature. 2010 Mar 11;464(7286):161-2. doi: 10.1038/464161a. No abstract available.

PMID:
20220821
44.

Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, Forthal DN, Koff WC, Poignard P, Watkins DI, Burton DR.

J Virol. 2010 Feb;84(3):1302-13. doi: 10.1128/JVI.01272-09. Epub 2009 Nov 11.

45.

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW; Protocol G Principal Investigators, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR.

Science. 2009 Oct 9;326(5950):285-9. doi: 10.1126/science.1178746. Epub 2009 Sep 3.

46.

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee DA, Manigart O, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Walker LM, Poignard P, Wrin T, Fast PE, Burton DR, Koff WC.

J Virol. 2009 Jul;83(14):7337-48. doi: 10.1128/JVI.00110-09. Epub 2009 May 13.

47.

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR.

PLoS Pathog. 2009 May;5(5):e1000433. doi: 10.1371/journal.ppat.1000433. Epub 2009 May 15.

48.

Macaques vaccinated with live-attenuated SIV control replication of heterologous virus.

Reynolds MR, Weiler AM, Weisgrau KL, Piaskowski SM, Furlott JR, Weinfurter JT, Kaizu M, Soma T, León EJ, MacNair C, Leaman DP, Zwick MB, Gostick E, Musani SK, Price DA, Friedrich TC, Rakasz EG, Wilson NA, McDermott AB, Boyle R, Allison DB, Burton DR, Koff WC, Watkins DI.

J Exp Med. 2008 Oct 27;205(11):2537-50. doi: 10.1084/jem.20081524. Epub 2008 Oct 6.

49.

Replicating viral vectors as HIV vaccines Summary Report from IAVI Sponsored Satellite Symposium, International AIDS Society Conference, July 22, 2007.

Koff WC, Parks CL, Berkhout B, Ackland J, Noble S, Gust ID.

Biologicals. 2008 Sep;36(5):277-86. doi: 10.1016/j.biologicals.2008.04.004. Epub 2008 Jun 13.

PMID:
18555698
50.

Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans.

Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC.

Nat Med. 2008 Jun;14(6):617-21. doi: 10.1038/nm.f.1759.

Supplemental Content

Support Center